TW201004658A - Nanoparticle compositions for nucleic acids delivery system - Google Patents

Nanoparticle compositions for nucleic acids delivery system Download PDF

Info

Publication number
TW201004658A
TW201004658A TW098125813A TW98125813A TW201004658A TW 201004658 A TW201004658 A TW 201004658A TW 098125813 A TW098125813 A TW 098125813A TW 98125813 A TW98125813 A TW 98125813A TW 201004658 A TW201004658 A TW 201004658A
Authority
TW
Taiwan
Prior art keywords
nanoparticle
peg
lipid
group
oligonucleotide
Prior art date
Application number
TW098125813A
Other languages
English (en)
Chinese (zh)
Inventor
Hong Zhao
lian-jun Shi
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of TW201004658A publication Critical patent/TW201004658A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW098125813A 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system TW201004658A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8528908P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
TW201004658A true TW201004658A (en) 2010-02-01

Family

ID=41610973

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098125813A TW201004658A (en) 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system

Country Status (6)

Country Link
US (1) US20110111044A1 (enExample)
EP (1) EP2304026A4 (enExample)
JP (1) JP2011529912A (enExample)
CA (1) CA2731173A1 (enExample)
TW (1) TW201004658A (enExample)
WO (1) WO2010014895A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103528A2 (en) * 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
JP2013524811A (ja) * 2010-04-20 2013-06-20 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ナノザイム、ナノザイムの製造方法、およびナノザイムの使用方法
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2915300A1 (en) * 2012-11-02 2015-09-09 Telefonaktiebolaget L M Ericsson (Publ) Network node, user node and methods for channel estimation
JP6360074B2 (ja) * 2013-01-03 2018-07-18 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチCouncil Of Scientific & Industrial Research マンノース受容体選択的リシニル化カチオン性両親媒性物質及びその調製方法
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
PL3019619T3 (pl) * 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015023715A1 (en) 2013-08-14 2015-02-19 The University Of Florida Research Foundation, Inc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
EP4101930A1 (en) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN107951862B (zh) * 2016-10-17 2021-03-12 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
CN111971066B (zh) * 2018-01-18 2025-03-11 伊泽阿恩埃免疫疗法股份有限公司 脂质纳米颗粒
US20210261964A1 (en) * 2018-07-19 2021-08-26 The Research Foundation For Microbial Diseases Of Osaka University LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CN109549934B (zh) * 2018-12-25 2021-03-09 上海交通大学 一种多糖基脂质纳米粒子的制备方法
KR20240027630A (ko) * 2021-06-01 2024-03-04 나노베이션 테라퓨틱스 인크. 지질 나노입자를 사용한 dna 벡터 전달
TWI851090B (zh) * 2022-03-17 2024-08-01 國立成功大學 雙股寡去氧核苷酸、包含該雙股寡去氧核苷酸的組合物及其用途
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
KR20240157096A (ko) 2022-03-23 2024-10-31 나노베이션 테라퓨틱스 인크. 고 스테롤-함유 지질 나노입자
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
JP7557915B2 (ja) * 2022-10-18 2024-09-30 株式会社チップトン テイラー反応装置及びカプセル粒子の製造方法
CN121568686A (zh) * 2023-07-24 2026-02-24 北京生命科学研究所 用于皮肤疾病局部治疗的脂质纳米颗粒组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
CA2256900A1 (en) * 1996-05-29 1997-12-04 Xiao-Ying Meng Cationic polymer/lipid nucleic acid delivery vehicles
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080207542A1 (en) * 2002-03-26 2008-08-28 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2597724A1 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2007090194A2 (en) * 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties

Also Published As

Publication number Publication date
WO2010014895A2 (en) 2010-02-04
JP2011529912A (ja) 2011-12-15
US20110111044A1 (en) 2011-05-12
CA2731173A1 (en) 2010-02-04
EP2304026A4 (en) 2013-12-18
WO2010014895A3 (en) 2010-05-27
EP2304026A2 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
TW201019969A (en) Branched cationic lipids for nucleic acids delivery system
US20110111044A1 (en) Nanoparticle compositions for nucleic acids delivery system
US20110305770A1 (en) Releasable polymeric lipids for nucleic acids delivery system
US20110229581A1 (en) Releasable cationic lipids for nucleic acids delivery systems
TW201021852A (en) Releasable fusogenic lipids for nucleic acids delivery systems
EP4497746A1 (en) Novel ionizable lipid and lipid nanoparticle composition using same
AU2019347774A1 (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
JP6240570B2 (ja) 脂質粒子および核酸送達キャリア
JPWO2016104580A1 (ja) カチオン性脂質
US20140080897A1 (en) Hyaluronic acid-nucleic acid conjugate and composition for nucleic acid delivery containing the same
JP5407862B2 (ja) siRNAおよび脂質性4,5−二置換2−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
JP2024541924A (ja) Poegmaベース脂質ナノ粒子
JP2023526277A (ja) 核酸リガンドコンジュゲートおよび細胞への送達のためのその使用
WO2025167726A1 (zh) 靶向载体、靶向药物及制备方法与应用
WO2025256540A1 (en) Compositions and method for targeted gene delivery
JP6495995B2 (ja) 脂質粒子および核酸送達キャリア
WO2026090175A2 (en) Propargyl amino-ionizable lipid compounds, lipid nanoparticles (lnps), and methods of making and using same for gene editing